Jennifer Chuy, MD
Hematology & Oncology · Bronx, NYNPI 1174826531
Payments from drug & device makers
What this record shows
This record is dominated by education: $120 of the $179 with a category attached, or 66.8%. 5 manufacturers reported payments, led by Astellas Pharma US Inc at 55.7% of the total. 2024 is the largest year on record at $116, 5.8 times the $20 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 5 payments — averaging $35.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$100
- Seagen Inc.$23
- Novartis$20
- Merck$20
- E.r. Squibb & Sons, L.L.C.$16
Across 107 payments — averaging $10,093 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Taiho Oncology, Inc.$761K
- Deciphera Pharmaceuticals Inc.$113K
- AstraZeneca$103K
- Astellas Pharma Global Development$69K
- E.r. Squibb & Sons, L.L.C.$24K
- Novartis$7K
- plus $3K from 3 others
What the payments were for
- Food & beverage$6033%
- Education$12067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 1 | $100 |
| Seagen Inc. | 1 | $23 |
| Novartis | 1 | $20 |
| Merck | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
How this compares
$179 in reported general payments places this provider in the 20th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $12,641 |
| Ondansetron OdtOndansetron | 22 | $315 |
| Pantoprazole Sodium | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Bronx
- Tauseef AhmedBronx$171K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.